Kamada (NASDAQ:KMDA) Given Buy (B-) Rating at Weiss Ratings

Key Points

• Kamada (NASDAQ:KMDA) received a "buy (B-)" rating from Weiss Ratings, which was reaffirmed in a recent report.
• The company's stock opened at $6.84 with a market cap of $393.33 million, showing a performance between its 52-week low of $5.18 and high of $9.15.
• Kamada reported $0.13 earnings per share for the last quarter, exceeding analysts' expectations, with revenue of $44.75 million for the period.

Kamada (NASDAQ:KMDA - Get Free Report)'s stock had its "buy (b-)" rating reiterated by analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Kamada Stock Performance

Shares of NASDAQ:KMDA opened at $6.84 on Wednesday. Kamada has a 52-week low of $5.18 and a 52-week high of $9.15. The company has a market capitalization of $393.33 million, a PE ratio of 20.12, a price-to-earnings-growth ratio of 0.68 and a beta of 0.84. The company has a fifty day moving average of $7.03 and a 200-day moving average of $7.00.

Kamada (NASDAQ:KMDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.04. Kamada had a return on equity of 7.41% and a net margin of 11.22%.The company had revenue of $44.75 million for the quarter, compared to the consensus estimate of $158.59 million. Kamada has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Kamada will post 0.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Kamada

A number of institutional investors have recently added to or reduced their stakes in the business. Trexquant Investment LP acquired a new position in Kamada in the 1st quarter valued at approximately $82,000. Cubist Systematic Strategies LLC acquired a new stake in Kamada in the first quarter valued at $206,000. Jump Financial LLC bought a new position in Kamada during the 2nd quarter worth $219,000. NewEdge Advisors LLC lifted its holdings in Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company's stock worth $341,000 after buying an additional 28,165 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Kamada during the 2nd quarter worth about $472,000. 20.38% of the stock is owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.